CTNM News

Eighteen IPOs raised a combined $5.3 billion in April, above the 10-year historical average by deal count and proceeds (16 IPOs, $3.7B). It was the busiest month for both overall new issuance and $100+ million IPOs since November 2021. Nine deals raised $100 million or more, led by the billion-dollar offering of cruise operator Viking (VIK). Large VC-backed tech...read more

Three IPOs priced in the first week of April, led by a sizable biotech. The calendar should see more activity coming up, thanks to some large launches and notable new filings. Neuro and inflammation biotech Contineum Therapeutics (CTNM) priced a downsized share offering at the low end to raise $110 million at a $429 million market cap. The company's lead asset is...read more

Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for inflammatory diseases, raised $110 million by offering 6.9 million shares at $16, the low end of the range of $16 to $18. The company offered 1.9 million fewer shares than anticipated. Contineum Therapeutics is focused on discovering and developing novel, oral small molecule therapies for the...read more

Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for IPF and multiple sclerosis, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Contineum Therapeutics would command a fully diluted market value of $490...read more